| Name | Title | Contact Details |
|---|
WaferGen Bio-systems, Inc. is an innovative life science company that offers innovative genomic solutions for clinical testing and research. The SmartChip MyDesign(TM) Real-Time PCR System is a high-throughput genetic analysis platform for profiling and validating molecular biomarkers via microRNA and mRNA gene expression profiling, as well as single nucleotide polymorphism (SNP) genotyping. The SmartChip TE(TM) System is a novel product offering for target enrichment geared towards clinical Next-Gen sequencing (NGS). The Company now also offers the Apollo 324(TM) product line used in library preparation for NGS. These three complementary technologies offer a powerful set of tools enabling more accurate, faster and cheaper genetic analysis based on Next-Gen Sequencing and Real-Time PCR.
PreViser Corporation is a Mount Vernon, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Carlsmed is transforming medicine by personalizing complex spine surgery to improve patient outcomes.
Johnson's Medical is a Lehi, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Smith & Nephew is a global advanced medical technology business. We support healthcare professionals in more than 100 countries to improve the quality of life for their patients. Since 1856, when our founder T.J. Smith developed a new method for refining cod liver oil, and in World War One when his nephew led the supply of wound care products, to the present day, Smith & Nephew continues to pioneer health solutions. Through our market leadership positions in Sports Medicine, Trauma, Orthopaedic Reconstruction and Advanced Wound Management, our 16,000 employees continue to improve outcomes and expand access, constantly striving to create value for healthcare professionals, patients, payers and shareholders. Annual sales in 2016 were more than $4.6 billion. We are a constituent of the UK’s FTSE100 and our shares are traded on London Stock Exchange and through American Depository Receipts on the New York Stock Exchange We have leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma. We have almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2013 were more than $4.3 billion. We are a constituent of the UK's FTSE100 and our shares are traded on the London Stock Exchange and through American Depository Receipts on the New York Stock Exchange (LSE: SN, NYSE: SNN)